Academic Journals Database
Disseminating quality controlled scientific knowledge

Risk of Venous Thromboembolism in Patients receiving Systemic Therapy for Early Breast Cancer

ADD TO MY LIST
 
Author(s): Julia Hoy | Alison Davis

Journal: The Asia-Pacific Journal of Oncology & Hematology
ISSN 1759-6637

Volume: 2;
Issue: 1;
Start page: 49;
Date: 2010;
VIEW PDF   PDF DOWNLOAD PDF   Download PDF Original page

Keywords: early breast cancer | systemic therapy | venous thromboembolism | chemotherapy

ABSTRACT
The association between malignancy and the development of venous thromboembolism (VTE) is well recognized. The incidence of VTE in early breast cancer (EBC) is lower than in metastatic disease and a number of other common malignancies, but still presents a significant problem in terms of morbidity and mortality. The risk of VTE is further increased in patients receiving adjuvant chemotherapy for EBC, with the reported incidence ranging from 1.5% to 16.6%. It is unknown which chemotherapeutic agents or regimens are associated with the highest risk. Hormonal therapy also increases risk, most notably tamoxifen, but also, to a lesser extent, the aromatase inhibitors. Molecular targeting agents such as trastuzumab and bevacizumab are entering routine clinical practice for breast cancer and, although trastuzumab has not been shown to increase VTE, bevacizumab has been linked to the development of both venous and arterial thrombosis. At present, the use of thromboprophylaxis is not recommended for ambulatory patients being treated for EBC. However, risk analysis tools are emerging that may play some role in identifying high-risk patients who would benefit from prophylactic anticoagulation in the future. More prospective research is required to establish the risk of VTE with different chemotherapy regimens as well as newer targeted therapies. For now, clinical vigilance is required to ensure early VTE detection and optimal management to reduce morbidity and mortality.

Tango Rapperswil
Tango Rapperswil

    
RPA Switzerland

RPA Switzerland

Robotic process automation